Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3740

Sort by

Sort Order Select

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2021) 137 (26): 3616–3628.

https://doi.org/10.1182/blood.2020008787

Published: 2021

Includes: Supplemental data

Journal Articles

Addition by subtraction

Sonja Zweegman, Tanya M. Wildes

Blood (2021) 137 (22): 3005–3006.

https://doi.org/10.1182/blood.2021011144

Published: 2021

Journal Articles

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Charles J. Milrod, Frances Blevins, David Hughes, Adam Lerner, Shayna Sarosiek, Vaishali Sanchorawala, J. Mark Sloan

Blood (2021) 137 (21): 2987–2989.

https://doi.org/10.1182/blood.2021010853

Published: 2021

Includes: Supplemental data

Journal Articles

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Blood (2021) 137 (16): 2267–2271.

https://doi.org/10.1182/blood.2020008609

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

Paolo Strati, Preetesh Jain, Ralph J. Johnson, Sheryl Forbes, Lei Feng, Felipe Samaniego, Maria A. Rodriguez, Luis E. Fayad, Fredrick Hagemeister, Jason Westin, Michael Wang, Sattva S. Neelapu, Loretta J. Nastoupil, Nathan H. Fowler

Blood (2021) 137 (8): 1124–1129.

https://doi.org/10.1182/blood.2020007994

Published: 2021

Includes: Supplemental data

Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood (2020) 136 (8): 936–945.

https://doi.org/10.1182/blood.2020005288

Published: 2020

Includes: Supplemental data

Journal Articles

Lenalidomide in follicular lymphoma

Christopher R. Flowers, John P. Leonard, Nathan H. Fowler

Blood (2020) 135 (24): 2133–2136.

https://doi.org/10.1182/blood.2019001751

Published: 2020

Journal Articles

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Blood (2020) 135 (16): 1396–1405.

https://doi.org/10.1182/blood.2019003526

Published: 2020

Includes: Supplemental data

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Zara Sayar, MD FRCPath, MRCP, Anna Weatherill, Stephen Keddie, Jonathan Sive, MD, Michael P Lunn, Mari Thomas, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 714.

https://doi.org/10.1182/blood-2019-125639

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

Blood (2019) 134 (Supplement_1): 1270.

https://doi.org/10.1182/blood-2019-128967

Published: 2019

Journal Articles

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Ashwin Kishtagari, MBBS, Hassan Awada, Reda Z. Mahfouz, MD PhD, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Alan Lichtin, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 1279.

https://doi.org/10.1182/blood-2019-130579

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Sunisa Kongkiatkamon, Anand Tiwari, Vera Adema, PhD, Cassandra M Kerr, MS, Bartlomiej Przychodzen, Hassan Awada, Jibran Durrani, Yvonne Parker, Drew Adams, Yuriy Fedorov, Hetty E. Carraway, MD MBA, Chao-Yie Yang, Mikkael A. Sekeres, MD MS, Daniel J. Lindner, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 881.

https://doi.org/10.1182/blood-2019-128671

Published: 2019

Journal Articles

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaoyi Wang, MD MPH, Rong Wang, PhD, Chi Zhang, MD MPH, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Scott F. Huntington, MD MPH, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 4748.

https://doi.org/10.1182/blood-2019-128821

Published: 2019

Journal Articles

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Paolo Milani, MD PhD, Francesca Fazio, MD, Marco Basset, MD, Tamara Berno, MD, Alessandra Larocca, Andrea Foli, MD, Marcello Riva, MD, Stefania Oliva, Jessica Ripepi, Mario Nuvolone, MD PhD, Maria Teresa Petrucci, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1860.

https://doi.org/10.1182/blood-2019-130675

Published: 2019

Journal Articles

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Smith Giri, MBBS, Peter Barth, MD, Luciano J. Costa, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 1862.

https://doi.org/10.1182/blood-2019-131231

Published: 2019

NARROW

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Addition by subtraction

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Lenalidomide in follicular lymphoma

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only